ANTHERA Trademark

Trademark Overview


On Wednesday, December 16, 2015, a trademark application was filed for ANTHERA with the United States Patent and Trademark Office. The USPTO has given the ANTHERA trademark a serial number of 86851675. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 18, 2019. This trademark is owned by Anthera Pharmaceuticals, Inc.. The ANTHERA trademark is filed in the Pharmaceutical Products, Advertising, Business and Retail Services, and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceuticals for the treatment of serious and life-threatening diseases, namely, lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis

Licensing late-stage clinical pharmaceutical products, namely, pharmaceuticals for the treatment of lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis

Developing clinical pharmaceutical products; research and development in the pharmaceutical and biotechnology fields
anthera

General Information


Serial Number86851675
Word MarkANTHERA
Filing DateWednesday, December 16, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 18, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, November 22, 2016

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of the wording "ANTHERA", surrounded by curved lines on the upper-left, upper-right, and lower-right, suggesting a circle around the wording.
Goods and ServicesPharmaceuticals for the treatment of serious and life-threatening diseases, namely, lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis
Goods and ServicesLicensing late-stage clinical pharmaceutical products, namely, pharmaceuticals for the treatment of lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis
Goods and ServicesDeveloping clinical pharmaceutical products; research and development in the pharmaceutical and biotechnology fields

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 22, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateTuesday, December 22, 2015
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, December 22, 2015
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAnthera Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHayward, CA 94545

Party NameAnthera Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHayward, CA 94545

Trademark Events


Event DateEvent Description
Tuesday, February 19, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 18, 2019ABANDONMENT - NO USE STATEMENT FILED
Thursday, July 19, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 17, 2018EXTENSION 3 GRANTED
Tuesday, July 17, 2018EXTENSION 3 FILED
Tuesday, July 17, 2018TEAS EXTENSION RECEIVED
Saturday, January 13, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 11, 2018EXTENSION 2 GRANTED
Thursday, January 11, 2018EXTENSION 2 FILED
Thursday, January 11, 2018TEAS EXTENSION RECEIVED
Wednesday, July 19, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 17, 2017EXTENSION 1 GRANTED
Monday, July 17, 2017EXTENSION 1 FILED
Monday, July 17, 2017TEAS EXTENSION RECEIVED
Tuesday, January 17, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 22, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 22, 2016PUBLISHED FOR OPPOSITION
Wednesday, November 2, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 18, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, October 13, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 6, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 6, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, October 2, 2016ASSIGNED TO LIE
Friday, September 23, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 31, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 31, 2016NON-FINAL ACTION E-MAILED
Thursday, March 31, 2016NON-FINAL ACTION WRITTEN
Thursday, March 31, 2016ASSIGNED TO EXAMINER
Wednesday, December 23, 2015NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, December 22, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, December 19, 2015NEW APPLICATION ENTERED IN TRAM